by Raynovich Rod | Apr 7, 2015 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Teva Deal Expands Portfolio and Diagnostic Capabilities Adding RXDX to Rayno Small Cap Portfolio Ignyta, Inc. (RXDX) is an emerging biopharmaceutical Company targeting new oncology drugs that inhibit Tyrosine kinase receptors (Trk) with integrated biomarker-based...
by Raynovich Rod | Mar 30, 2015 | 2025 Rayno Biopharmaceuticals Portfolio
Global Rally Today But Healthcare Sector Lags A Bit DOW up 1.49% at 17,976 NASDAQ Up 1.15% at 4947 Healthcare up 0.93% We are in Day Two of the biotech rally that was sparked last Friday with the rumor supported by a Deutsche Bank analyst that Biomarin (BMRN) was a...
by Raynovich Rod | Mar 23, 2015 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update 3/25 Mid-Day Trading NAZ Off 1.55% at 4917 “Bubble Talk” Picking Up-Mid Caps Vulnerable Biotech sector selling picked up today with a dramatic shift in sentiment exacerbated by an overall weak market. Also durable goods fell unexpectedly 1.4% in...
by Raynovich Rod | Mar 20, 2015 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Biotech and Healthcare ETFs Hit An All Time High–Another Rally Coming Today 3/20 M&A: Recent buy-outs of Cubist (CBST) for $9.5B and Pharmacyclics (PCYC) for $21B have raised the valuation bar. The healthcare sector remains strong and biopharmaceuticals are...
by Raynovich Rod | Mar 16, 2015 | 2024 Rayno Tools and Diagnostics Portfolio, 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
March 18-Stealth Rally With A Tempered Tape In Biotech NASDAQ up 0.92% Biotech stocks lagged the surprising FED rally today maybe because money was moving to other sectors.This bears close watching because only this week biotech stocks hit a new high.Money may be...
by Raynovich Rod | Mar 10, 2015 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals, Macro
Stocks in Sharp Sell-Off on Potential FED Rate Increase and Strong Dollar Deflation is Still Lurking S&P Down 1.7%, NASDAQ down 1.67% Biotech stocks avoided the severe sell-off today apparently immune to the strong dollar, flat earnings growth and FED interest...
by Raynovich Rod | Mar 4, 2015 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Whoa! $261.25 And the winner is Abbvie (ABBV) for $21B! Pharmacyclics Buzz Is Back Biotech stocks covered the green screen today, despite a listless general market, driven by deal talk regarding Pharmacyclics (PCYC). Q4 2014 sales of their potential blockbuster drug...
by Raynovich Rod | Mar 2, 2015 | Biopharmaceuticals
Update-1… On Onyx $10.4B Buyout By Amgen (AMGN) Valuation Models for Biopharma Stocks -M&A Update In October 2013 we compared emerging biotech stocks after the acquisition of Onyx Pharmaceuticals by Amgen (AMGN). Now that rumors are “out there”...
by Raynovich Rod | Feb 25, 2015 | 2025 Rayno Biopharmaceuticals Portfolio
2/27 Friday After a big February biotechs turned red today with major ETFs off about 1%. In light of recent M&A talk about Pharmacyclics, Inc. (PCYC) at Market Cap of $16.6B we will look at other top Mid-Cap biopharmaceutical stocks for comparison to our motif...
by Raynovich Rod | Feb 13, 2015 | Biopharmaceuticals
What will it take to drive the biotech sector to new highs? As we approach new highs for the biotech sector in 2015 here are some market trends to watch as the technicals get a little choppy. The next major indicator will be 2015 Q1 earnings. Stay tuned. Momentum of...
